| Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share |
The following common stock equivalents were excluded from the computation of diluted net loss per share attributable to common stockholders of BridgeBio, because including them would have been antidilutive: | | | | | | | | | | | | | | | As of September 30, | | 2026 | | 2025 | | | | Unvested RSUs | 7,997,782 | | 10,694,969 | | | | Unvested performance-based RSUs | 285,973 | | 194,943 | | | | Unvested market-based RSUs | — | | 375,000 | | | | Common stock options issued and outstanding | 9,779,350 | | 11,909,994 | | | Estimated shares issuable under performance-based milestone
compensation arrangements | 1,735,060 | | 1,330,341 | | | | Estimated shares issuable under the ESPP | 39,429 | | 42,842 | | | | Assumed conversion of 2027 Notes | 12,878,305 | | 12,878,305 | | | | Assumed conversion of 2029 Notes | 7,702,988 | | 7,702,988 | | | | Assumed conversion of 2031 Notes | 11,544,448 | | 11,544,448 | | | | Assumed conversion of 2033 Notes | 5,720,014 | | — | | | | Assumed conversion of Preferred Stock | 6,777,704 | | — | | | | 64,461,053 | | 56,673,830 | | |
|